Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
AD1058
AOB13929
CAS: 2907782-78-7
Chemical Name: (R)-3-Methyl-4-(7-(methylsulfonyl)-2-(6-(trifluoromethyl)-1H-indol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)morpholine
1000 Items
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $31.45 | Total: $157.25 |
| 1 | 10 | $26.64 | Total: $266.40 |
| 1 | 25 | $22.57 | Total: $564.25 |
| 1 | 50 | $19.24 | Total: $962.00 |
| 1 | 100 | $16.65 | Total: $1,665.00 |
Overview
Novel, Highly Potent, Selective, and Brain-Penetrant ATR Inhibitor for the Treatment of Advanced Malignancies
Chemical Properties
| Molecular Formula | C19H20N6O3S |
| Molecular Weight | 412.47 |
| CAS Numbers | 2907782-78-7 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| IUPAC/Chemical Name | (R)-3-Methyl-4-(7-(methylsulfonyl)-2-(6-(trifluoromethyl)-1H-indol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)morpholine |
| SMILES Code | O=S(N1C=CC2=C(N3[C@H](C)COCC3)N=C(C4=C5C(NC=C5)=NC=C4)N=C21)(C)=O |
Storage and Handling
0C Short Term -20C Long Term
References
1) Liu Z, Jiang K, et al. Discovery of Preclinical Candidate AD1058 as a Highly Potent, Selective, and Brain-Penetrant ATR Inhibitor for the Treatment of Advanced Malignancies. J Med Chem. 2024 Aug 8;67(15):12735-12759